Document:

Employment Agreement

 Exhibit 10.108 
 February 8, 2006 
 Mr. Richard Segil 
 14363
Trailwind Road 
 Poway, CA 92064 
 Dear Mr. Segil:

 Path 1 Network Technologies, Inc. is a leader in broadcast quality video transport over IP technology. We are committed to developing world-class,
cutting-edge products and to providing our employees a dynamic workplace that fosters innovation. 
 We are excited that you have expressed an interest in
joining our team and believe your capabilities and professional aspirations match Path 1’s needs and high expectations. We are therefore pleased to make the following offer of employment. 
  

			
	Position:	  	Vice President, Marketing
		
	Reporting to:	  	Thomas Tullie
		
	Classification:	  	Full Time, Exempt
		
	Base Salary:	  	You will receive a base salary of $7,500.00 per pay period (annualized rate of $180,000) in accordance with Path 1’s standard payroll cycle, which is currently
semi-monthly.
		
	Performance Bonus:	  	Provided that you meet achievement milestones established by the President and CEO, and subject to approval of the bonus pool and individual participation by the Board of Directors of Path 1
(the “Board”), you will be eligible to receive a performance bonus of up to a maximum of twenty-five percent (25%) of your Base Salary.

  

 Page 1 of 4 

			
		
	Stock Options:	  	Subject to Board approval, stock options on 70,000 shares of Common Stock with an exercise price at fair market value on the date of grant, vesting in sixteen (16) equal quarterly
installments over a period of four (4) years in accordance with the Company’s 2000 or 2004 Stock Option/Stock Issuance Plans.
		
	Restricted Stock:	  	Subject to Board approval, 30,000 restricted shares pursuant to the 2000 or 2004 Stock Option/Stock Issuance Plan. The restricted stock shall vest in sixteen (16) equal quarterly installments
over a period of four (4) years.
		
	Benefits:	  	As an employee of Path 1 you will be eligible to participate in the standard benefits programs for yourself and your eligible dependents. These benefits begin on the first of the month
following your date of employment.
		
	Paid Time Off:	  	In consideration of your position with Path 1, your PTO will accrue at the rate of 6.67 hours per pay period for a total of 160 hours or four (4) weeks per year.
		
	Severance:	  	Three (3) months severance in the form of salary continuation in case of termination for any reason other than for cause, effective after ninety (90) days of employment. The severance will be
paid only upon the signing of a Release of Claims by you. Subject to this severance arrangement, you shall be an “at-will” employee and your employment can be terminated at any time by Path 1.
		
	Start Date:	  	February 9th, 2006
		
	Offer Expiration Date:	  	February 9th, 2006

  

 Page 2 of 4 

 You must sign Path 1 Network Technologies’ Proprietary Information and Invention Agreement on your first day of
employment. The benefits package consists of a choice of three medical care programs provided by PacifiCare with a contribution by the employee, company paid dental, vision, Life and LTD, and a chiropractic program which is paid for by employees if
they wish to participate. We provide a holiday schedule that includes at least 11 assigned or floating holidays. We also offer a 401(k) plan and a Section 125 program. 
 The employment relationship between Path 1 Network Technologies, Inc. and its employees is for an unspecified term and may be terminated by the employee or Path 1 at any time, with or without cause or advance notice.
This offer is not intended to create any contractual obligations that in any way conflict with the company’s policy of at-will employment. An employment agreement will be put in place with the intent that the terms of the agreement will
co-exist with standard California at-will employment conditions. 
 This offer of at-will employment is contingent upon successful completion of appropriate
proof of eligibility to work in the United States (please provide confirming information on your first day of work) and successful completion of the background check process. 
 This written offer of employment contains our complete offer. Any representations, whether written or oral, not contained in this letter are expressly cancelled and superseded by this offer. 
 Please sign and date the attached approval and acceptance and return to Human Resources. 
 Sincerely, 
  

	
	
	/S/ Thomas L. Tullie
	 Thomas L. Tullie
 President &
CEO

  

 Page 3 of 4 

 I understand that employment with Path 1 Network Technologies Inc. is not for a specified term, and is at the mutual
consent of the employee and the company. Accordingly, either the employee or the company can terminate the employment relationship at will, with or without cause, at any time. My signature below memorializes my full understanding and acceptance of
this offer of employment. 
  

					
	Approved and Accepted	 		 	
			
	/S/ Richard Segil	 		 	February 9, 2006
	Richard Segil	 		 	Date

  

 Page 4 of 4Castle Creek Consent and Waiver

 Exhibit 10.109 
 CONSENT AND WAIVER 
 This consent and waiver is given on April 22, 2006 by Castle Creek
Technology Partners LLC (“CC”) to and with regard to Path 1 Network Technologies Inc. (“Path 1”). CC holds 476,927 shares of Path 1’s Series B 7% Convertible Preferred Stock (“Series B Preferred
Stock”) and 246,154 Path 1 common stock warrants, acquired pursuant to a Securities Purchase Agreement dated April 26, 2005 among Path 1, CC and others (the “Purchase Agreement”). This consent and waiver relates to
Path 1’s proposed April 2006 revolving-line-of-credit-plus-warrants financing transaction (the “Transaction”) with Laurus Master Fund, Ltd. 
 1. CC, on its own behalf and as the holder of a majority of Path 1’s outstanding Series B Preferred Stock and as the holder of a majority in interest of the outstanding Registrable Securities (on an
as-converted/as-exercised basis, as defined in the Purchase Agreement), hereby 
 (a) Consents under Section 10 of Path 1’s Series
B Preferred Stock’s certificate of designations (the “Certificate”) to the consummation of the Transaction and the issuance of the securities contemplated by the Transaction (including, without limitation, any shares issued in
the future upon exercise of Transaction warrants). It is understood that, if and to the extent the consummation of the Transaction and the issuance of the securities require the consent of a majority of the Series B Preferred Stock pursuant to the
Certificate, this consent and waiver shall constitute such consent. 
 (b) Waives, pursuant to Section 8.3 of the Purchase Agreement any
application of Section 3.7 of the Purchase Agreement to the Transaction and to the issuance of the securities contemplated by the Transaction (including, without limitation, any shares issuable or issued in the future upon exercise of
Transaction warrants (inclusive of the warrants themselves, the “Warrant Shares”)). It is understood that, if and to the extent the consummation of the Transaction and the issuance of the securities contemplated by the Transaction
(including, without limitation, any Warrant Shares) require the consent of a majority in interest of the outstanding Registrable Securities (on an as-converted/as-exercised basis, as defined in the Purchase Agreement) pursuant to the Purchase
Agreement, this consent and waiver shall constitute such consent. 
 (c) Waives and renounces any antidilution adjustments to which CC (or
CC’s assignees) may be entitled pursuant to CC’s Series B Preferred Stock and related warrants (“Preferred Securities”) to the extent (and only to the extent) that such antidilution adjustments are or may in the future be
triggered by any of: 
 (i) the consummation of the Transaction and the issuance of the Warrant Shares); 
 (ii) the extension of the new rights described herein to any of the other holders of Preferred Securities or other Preferred Stock or
warrants; 
 (iii) the issuance of any new Path 1 securities to any of the other holders of Preferred Securities pursuant to
the terms and conditions hereof; and 
 (iv) the potential or actual issuance of any new Path 1 securities to any holders of
other Path 1 derivative securities by virtue of any antidilution adjustments occurring as a result of (i), (ii) or (iii) above. 
 In the event that a material amendment, modification or supplement is made in or to a contract with or for the benefit of Laurus (or its assignees) relating to the Transaction, without CC’s prior written consent, then this antidilution
waiver shall not apply from and after the time of such material amendment, 

 
modification or supplement with regard to any issuance above and beyond issuances that would have been called for by the Transaction documents as they stood
immediately before such material amendment, modification or supplement. 
 2. Path 1 shall, unless and until the Certificate is amended to
reduce the Conversion Price of the Series B Preferred Stock to the initial Warrant Shares exercise price or lower, or until by operation of the Certificate as it stands the Conversion Price is reduced to the initial Warrant Shares exercise price or
lower, treat (as to CC) the Conversion Price as being the initial Warrant Shares exercise price in the following manner: when and if CC converts any of its Series B Preferred Stock in accordance with the Certificate), then, if (i) the
number of new shares of Path 1 Common Stock issued in such conversion is less than (ii) the number of new shares of Path 1 Common Stock which would have been issued to CC upon conversion of the same number of shares of Series B Preferred Stock
if the Conversion Price in the Certificate were the initial Warrant Shares exercise price, then Path 1 shall promptly also issue to CC that exact number of new shares of Path 1 Common Stock that equals the difference between (i) above and
(ii) above (all subject to adjustments for any stock splits, reverse stock splits, stock dividends on or recapitalizations of the Series B Preferred Stock). 
 3. This consent and waiver shall be governed by and construed in accordance with California law. This consent and waiver cannot be amended, terminated or waived except in a writing signed by both parties. Each party
represents and warrants that no promise, inducement or agreement not expressed herein has been made to it in connection with this instrument. This consent and waiver contains the entire agreement between the parties with respect to the subject
matter hereof and supersedes any previous agreement between the parties with regard thereto. In every other respect, the parties’ previous agreements, including but not limited to, the Purchase Agreement and the Certificate and a Settlement
Agreement dated February 10, 2006, remain in full force and effect. 
 4. Each respective other holder of Series B Preferred Stock is,
to the extent set forth in this Section 4, a direct and intended third-party beneficiary of this consent and waiver. Each respective other holder of Series B Preferred Stock is entitled, as a third-party beneficiary of this consent and waiver,
to receive all the same benefits of CC under this consent and waiver, as if the references to CC in this consent and waiver were references to such holder, by sending a written notice to Path 1 that it wishes to receive the same benefits as CC and
be subject to the same burdens as CC as set forth in this consent and waiver, as if the references to CC in this consent and waiver were references to such holder. However, even if a holder does not do so, its rights can nonetheless be affected by
waivers and consents given by CC herein in its capacity as a majority holder. 
 5. The parties may disagree as to whether issuance of
securities in the Transaction require consent of a majority of Path 1’s outstanding Series B Preferred Stock pursuant to Section 10(iii) of the Certificate. The parties confirm that, notwithstanding the consent and waiver given herein as
to the Transaction, each reserves its rights and respective interpretations under the Certificate as to the Transaction specifically and also should any similar situation ever recur. This consent and waiver will not for any purpose be deemed an
admission by either party; provided, however, CC agrees that for the purpose of determining whether the Stock Payment Condition as defined in the Certificate (and in Path 1’s 7% Convertible Preferred Stock certificate of designations) has been
met, the Transaction shall be deemed not to have resulted in a Fundamental Change (as defined therein). 
  

 - 2 - 

			
	 PATH 1 NETWORK TECHNOLOGIES INC.

		
	 By:
	 	  
		 	 Tom Tullie

		 	 Chief Executive Officer

  

					
	 CASTLE CREEK TECHNOLOGY PARTNERS LLC

		
	By:	 	 Castle Creek Partners, LLC,
 Investment
Manager

			
		 	 By:
	 	  
		 		 	

  

 - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]